Celgene Competitors and Similar CompaniesClear all

Celgene's competitors and similar companies include Sanofi, Idorsia, Amgen, Gilead Sciences and Regeneron Pharmaceuticals.
Celgene
Celgene
Celgene is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory diseases.
Sanofi
Sanofi
Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
Idorsia
Idorsia
Idorsia, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs.
Amgen
Amgen
Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.
Gilead Sciences
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines.
Founding Date
Founding Date
1986
Founding Date
2004
Founding Date
2017
Founding Date
1980
Founding Date
1987
Founding Date
1988
Type
Type
Subsidiary
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Summit, US HQ
Singapore, SG
Boudry, CH
Locations
Paris, FR HQ
Hydra, DZ
Macquarie Park, AU
Wien, AT
Dhaka, BD
Brussel, BE
Geel, BE
see more
Locations
Allschwil, CH HQ
Shanghai, CN
Lörrach, DE
Chiyoda City, JP
Locations
Thousand Oaks, US HQ
Hydra, DZ
Vicente López, AR
Sydney, AU
Wien, AT
Diegem, BE
Santo Amaro, BR
see more
Locations
Foster City, US HQ
Buenos Aires, AR
Melbourne, AU
Wien, AT
Machelen, BE
São Paulo, BR
Edmonton, CA
see more
Locations
Tarrytown, US HQ
Mississauga, CA
Courbevoie, FR
München, DE
Bengaluru, IN
Dublin, IE
Limerick, IE
see more
Employees
Employees
8,85219% increase
Employees
86,088
Employees
8007% increase
Employees
25,200
Employees
18,0006% increase
Employees
13,9264% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
141.1 b
Valuation ($)
N/A
Valuation ($)
170.4 b
Valuation ($)
110.5 b
Valuation ($)
102.2 b

Financial

Revenue (est.)
Revenue (est.)
$15.3b (FY, 2018)
Revenue (est.)
€43.1b (FY, 2023)
Revenue (est.)
CHF152.4m (FY, 2023)
Revenue (est.)
$28.2b (FY, 2023)
Revenue (est.)
$27.1b (FY, 2023)
Revenue (est.)
$13.1b (FY, 2023)
Cost of goods
Cost of goods
$587m (FY, 2018)
Cost of goods
€12.5b (FY, 2023)
Cost of goods
CHF7.2m (FY, 2023)
Cost of goods
$8.5b (FY, 2023)
Cost of goods
$6.5b (FY, 2023)
Cost of goods
N/A
Gross profit
Gross profit
$14.7b (FY, 2018)
Gross profit
€34.5b (FY, 2023)
Gross profit
CHF146.4m (FY, 2023)
Gross profit
$19.7b (FY, 2023)
Gross profit
$20.6b (FY, 2023)
Gross profit
N/A
Net income
Net income
$4b (FY, 2018)
Net income
€5.6b (FY, 2023)
Net income
(CHF297.9m) (FY, 2023)
Net income
$6.7b (FY, 2023)
Net income
$5.6b (FY, 2023)
Net income
$4b (FY, 2023)

Operating

Countries
Countries
N/A
Countries
N/A
Countries
N/A
Countries
100 (FY, 2020)
Countries
35 (FY, 2021)
Countries
N/A
Patents (EU)
Patents (EU)
N/A
Patents (EU)
N/A
Patents (EU)
N/A
Patents (EU)
21 (FY, 2020)
Patents (EU)
N/A
Patents (EU)
17 (FY, 2020)
Patents (US)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
31 (FY, 2020)
Patents (US)
N/A
Patents (US)
31 (FY, 2020)
Phase I Trials Products (Oncology)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
9 (FY, 2021)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
7 (FY, 2019)
Phase I Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
12 (FY, 2021)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
1 (FY, 2021)
Phase II Trials Products (Oncology)
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
11 (FY, 2020)
Phase III Trials Products
9 (FY, 2021)
Phase III Trials Products
N/A
Products
Products
N/A
Products
N/A
Products
N/A
Products
N/A
Products
21 (FY, 2021)
Products
11 (FY, 2022)
Projects in R&D Pipeline
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
91 (FY, 2019)
Projects in R&D Pipeline
12 (FY, 2019)
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 310m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 53.9m
For sources of this data, please see the company profile

View Company Profiles

Sanofi
HQ
Paris, FR
Employees
86,088

Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.

View company
Idorsia
HQ
Allschwil, CH
Employees
800↑ 7% increase

Idorsia, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs.

View company
Amgen
HQ
Thousand Oaks, US
Employees
25,200

Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.

View company
Gilead Sciences
HQ
Foster City, US
Employees
18,000↑ 6% increase

Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.

View company